Press release
March 17, 2025
Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
Latigo Biotherapeutics, Inc. (LTGO)
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board Proceeds support advancement of company’s Na v 1.8 inhibitor clinical programs and development of broader pipeline THOUSAND OAKS, Calif. – March 17, 2025 – Latigo Biotherapeutics